Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

CAMBRIDGE, Mass. and KRAKOW, Poland, Sept. 16, 2013 /PRNewswire/ -- H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It has also implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts. Selvita started its first kinase discovery programs in 2008 and, over the last five years, has built a premium scientific team with one of the world's most robust kinase discovery platforms. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

"Our goal at H3 Biomedicine is to – in a very focused way – utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," stated

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
(Date:10/30/2014)... James Sherley says he has been working towards ... technology since his days as a principal investigator at the ... 1990’s. Sherley founded the ASCTC as a new Boston ... intellectual property developed in Sherley’s research over the years since ... Technology (MIT), and more recently as a senior scientist at ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/27/2014)... 2014 Ryan Carfley , Managing Partner ... sit down with Bryan Hamilton, the publisher of the Triangle ... talent in the Research Triangle region of North Carolina. , ... at the roundtable include the role of social media ... work/life balance and the unique role that Millennials play in ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a ... a biotechnology company focused on developing highly effective ... and Virus-Like Particles (VLPs), today announced that company ... and U.S. Congressman David Price (D-NC), are holding ...
... Market Presence in PRC Healthcare Laboratory Market -- re> SINGAPORE and HONG KONG, Sept. 30 /PRNewswire-Asia/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. ... (NASDAQ: OGXI ) announced today the initiation ... (also known as OGX-011/TV-1011) as first line therapy for ... trial is the second of three Phase 3 trials ...
Cached Biology Technology:Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 2Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 4Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 5Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 6Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 7Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 8TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 2TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 3TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 4TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 5TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 6
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... York City on September 19, 2014, leading geneticist and ... of Genome Sciences and Medicine at the University of ... of Tel Aviv University, was awarded the 2014 Lasker-Koshland ... to her honorary degree from TAU, Prof. King was ... Medicine, and for the past 18 years she has ...
(Date:10/29/2014)... MA and Hebei, China — BGI Tech and Hebei ... of the Jujube genome. Jujube is the most economically ... genome is particularly difficult to sequence due the high ... the first time that a genome in the Rhamnaceae ... recently published in Nature Communications . ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2
... the Pacific Northwest, where rainfall averages only 4 to ... owners and wine grape producers. The arid conditions in ... for vineyard owners who produce and market high-quality wine ... fails to deliver, vineyard managers in the area typically ...
... the 1980s Dr. Joseph M. Prospero, professor of Marine ... School of Marine and Atmospheric Science, has pioneered studies ... in the atmosphere and carried by winds. His teams ... atmosphere. They are particularly interested in the long-range transport ...
... IMMEDIATE RELEASE New-generation artificial cornea could restore ... An improved artificial cornea, which could restore the vision ... blind due to diseased corneas, finally is moving toward ... of research on the topic. Their study is scheduled ...
Cached Biology News:Study results: new recommendations for grape growers 2Study in Science cites impact of anthropogenic nitrogen on ocean biology, atmospheric CO2 2American Chemical Society's Weekly PressPac -- May 14, 2008 2American Chemical Society's Weekly PressPac -- May 14, 2008 3American Chemical Society's Weekly PressPac -- May 14, 2008 4American Chemical Society's Weekly PressPac -- May 14, 2008 5American Chemical Society's Weekly PressPac -- May 14, 2008 6American Chemical Society's Weekly PressPac -- May 14, 2008 7American Chemical Society's Weekly PressPac -- May 14, 2008 8
ANTI S. ENT TOX BC2D...
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: